Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape

Nature Medicine

Volumn 18, Issue 11, 2012, Pages 1688-1692

  Moore, Penny L ^a,b   Gray, Elin S ^a   Wibmer, C Kurt ^a,b   Bhiman, Jinal N ^a,b   Nonyane, Molati ^a   Sheward, Daniel J ^b   Hermanus, Tandile ^a   Bajimaya, Shringkhala ^d   Tumba, Nancy L ^a   Abrahams, Melissa Rose ^c   Lambson, Bronwen E ^a   Ranchobe, Nthabeleng ^a   Ping, Lihua ^e   Ngandu, Nobubelo ^c   Karim, Quarraisha Abdool ^f   Karim, Salim S Abdool ^f   Swanstrom, Ronald I ^e   Seaman, Michael S ^d   Williamson, Carolyn ^c   Morris, Lynn ^a,b  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ASPARAGINE; BROADLY CROSS NEUTRALIZING ANTIBODY; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PGT128; NEUTRALIZING ANTIBODY; PLACEBO; TENOFOVIR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; VIRUS STRAIN; VIRUS TRANSMISSION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; EPITOPES; EVOLUTION, MOLECULAR; FEMALE; GENOME, VIRAL; HIV; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; POLYSACCHARIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869155712     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2985     Document Type: Article

References (36)

1. Haynes, B.F. & Montefiori, D.C. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5, 347-363 (2006 (Pubitemid 44167156)
2. Hu, S.L. & Stamatatos, L. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5, 507-513 (2007 (Pubitemid 351210986)
3. Phogat, S. & Wyatt, R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13, 213-227 (2007 (Pubitemid 46085294)
4. Li, Y. et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83, 1045-1059 (2009
5. Sather, D.N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009
6. Simek, M.D. et al. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337-7348 (2009
7. Stamatatos, L., Morris, L., Burton, D.R. & Mascola, J.R. Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine? Nat. Med. 15, 866-870 (2009
8. Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011
9. Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144-4149 (2003 (Pubitemid 36418171)
10. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003 (Pubitemid 36378357)
11. Frost, S.D. et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. USA 102, 18514-18519 (2005 (Pubitemid 43011257)
12. Gray, E.S. et al. Antibody specificities associated with neutralization breadth in plasma from HIV-1 subtype C infected blood donors. J. Virol. 83, 8925-8937 (2009
13. Tomaras, G.D. et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85, 11502-11519 (2011
14. Walker, L.M. et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6, e1001028 (2010
15. Gray, E.S. et al. HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011
16. Nandi, A. et al. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396, 339-348 (2010
17. Tang, H. et al. epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. J. Virol. 85, 9286-9299 (2011
18. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009
19. Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103 (2011
20. Abrahams, M.R. et al. Quantitating the multiplicity of infection with HIV-1 subtype C reveals a non-Poisson distribution of transmitted variants. J. Virol. 83, 3556-3567 (2009
21. Moore, P.L. et al. The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 82, 1860-1869 (2008 (Pubitemid 351206934)
22. Moore, P.L. et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5, e1000598 (2009
23. Gray, E.S., Moore, P.L., Pantophlet, R.A. & Morris, L. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J. Virol. 81, 10769-10776 (2007 (Pubitemid 47463349)
24. Binley, J.M. et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78, 13232-13252 (2004 (Pubitemid 39507829)
25. Bures, R. et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J. Virol. 76, 2233-2244 (2002 (Pubitemid 34150691)
26. Gray, E.S., Meyers, T., Gray, G., Montefiori, D.C. & Morris, L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 3, e255 (2006
27. Zhang, M. et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14, 1229-1246 (2004 (Pubitemid 39585357)
28. Gnanakaran, S. et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 7, e1002209 (2011
29. Bunnik, E.M. et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 16, 995-997 (2010
30. Salazar-Gonzalez, J.F. et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82, 3952-3970 (2008 (Pubitemid 351521232)
31. Gorny, M.K. & Zolla-Pazner, S. Immunoprophylaxis against mother-to-child transmission of HIV-1. PLoS Med. 3, e259 (2006
32. Walker, L.M. et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. USA 108, 20125-20129 (2011
33. van Loggerenberg, F. et al. Establishing a cohort at high risk of HIV infection in South Africa: Challenges and experiences of the CAPRISA 002 acute infection study. Plos One 3, e1954 (2008
34. Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010
35. Gao, F. et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J. Virol. 70, 1651-1667 (1996 (Pubitemid 26062925)
36. Gray, E.S. et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81, 6187-6196 (2007 (Pubitemid 46878025)